Medium vs Low Oxygen Threshold for the Surfactant Administration

Respiratory Distress Syndrome Clinical Trial

Official title:

Comparison of Two Fraction Oxygen Inspired (FiO2) Thresholds for the Surfactant Administration in Preterm Infants With Respiratory Disease Syndrome: a Single-center Randomized Phase IV Clinical Trial

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04199364
• Other study ID #: 2535
• Secondary ID: 2019-002923-13
• Status: Not yet recruiting
• Phase: Phase 4
• Start date: June 1, 2021
• Est. completion date: April 30, 2025

Study information

• Verified date: April 2021
• Source: Ospedali Riuniti Ancona
• Contact: Virgilio Carnielli, MD, PHD
• Phone: 0715962045
• Email: v.carnielli[@]staff.univpm.it
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this study will be to assess the better fraction inspired oxygen (FiO2) threshold for the surfactant treatment in preterm infants with respiratory distress syndrome (RDS) randomized to receive exogenous surfactant at 25% or 35% of FiO2 threshold. The pulmonary gas-exchanges will be evaluated by oxygen saturation (SpO2) to FiO2 ratio (SFR) and will be used to define the better FiO2 threshold for the surfactant treatment.

Description:

Exogenous surfactant therapy is an effective treatment of neonatal respiratory distress syndrome (RDS) and has been associated with reduced severity of respiratory distress and mortality. The 2019 European guidelines for neonatal RDS treatment suggest as the threshold of inspired oxygen (FiO2) for the surfactant treatment at 30% for all gestational age, but there are no randomized studies that confirm this indication. Some observational studies reported that a relevant number of patients who are not routinely treated with surfactant had respiratory complications, thus they received exogenous surfactant. To date, the optimal FiO2 threshold for surfactant administration remains unclear.

In this single-center, randomized, phase 4 trial, preterm infants (gestational age<32 weeks) with RDS will be randomized to receive exogenous surfactant at 25% or 35% of FiO2 threshold. According to the unit policy, the exogenous surfactant will be administered by an endotracheal tube in intubated infants, or by Intubation-Surfactant-Extubation (InSurE) / Less Invasive Surfactant Administration (LISA) methods in infants who will not remain intubated. The method used for the surfactant administration will be at the discretion of the caring physician.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 200
• Est. completion date: April 30, 2025
• Est. primary completion date: July 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 24 Weeks to 32 Weeks

Eligibility

Inclusion Criteria:

• gestational age less than 32 weeks;

• diagnosis of respiratory distress (RDS);

• need for ventilatory support;

• written informed consent.

Exclusion Criteria:

• congenital malformations;

• genetic disorders;

• perinatal asphyxia.

• neonatal pneumonia or wet lung or meconium aspiration syndrome at birth.

Related Conditions & MeSH terms

• Respiratory Distress Syndrome
• Respiratory Distress Syndrome, Adult
• Respiratory Distress Syndrome, Newborn
• Syndrome

Intervention

Drug:
• Poractant Alfa 80 mg/mL Intratracheal Suspension
Exogenous surfactant (Poractant Alfa) administration at a dose of 200 mg/kg.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Virgilio Paolo Carnielli

References & Publications (19)

Ammari A, Suri M, Milisavljevic V, Sahni R, Bateman D, Sanocka U, Ruzal-Shapiro C, Wung JT, Polin RA. Variables associated with the early failure of nasal CPAP in very low birth weight infants. J Pediatr. 2005 Sep;147(3):341-7. — View Citation

Dargaville PA, Aiyappan A, De Paoli AG, Dalton RG, Kuschel CA, Kamlin CO, Orsini F, Carlin JB, Davis PG. Continuous positive airway pressure failure in preterm infants: incidence, predictors and consequences. Neonatology. 2013;104(1):8-14. doi: 10.1159/000346460. Epub 2013 Apr 4. — View Citation

Dargaville PA, Gerber A, Johansson S, De Paoli AG, Kamlin CO, Orsini F, Davis PG; Australian and New Zealand Neonatal Network. Incidence and Outcome of CPAP Failure in Preterm Infants. Pediatrics. 2016 Jul;138(1). pii: e20153985. doi: 10.1542/peds.2015-3985. — View Citation

De Jaegere AP, van der Lee JH, Canté C, van Kaam AH. Early prediction of nasal continuous positive airway pressure failure in preterm infants less than 30 weeks gestation. Acta Paediatr. 2012 Apr;101(4):374-9. doi: 10.1111/j.1651-2227.2011.02558.x. Epub 2012 Jan 9. — View Citation

Engle WA; American Academy of Pediatrics Committee on Fetus and Newborn. Surfactant-replacement therapy for respiratory distress in the preterm and term neonate. Pediatrics. 2008 Feb;121(2):419-32. doi: 10.1542/peds.2007-3283. — View Citation

Fuchs H, Lindner W, Leiprecht A, Mendler MR, Hummler HD. Predictors of early nasal CPAP failure and effects of various intubation criteria on the rate of mechanical ventilation in preterm infants of <29 weeks gestational age. Arch Dis Child Fetal Neonatal Ed. 2011 Sep;96(5):F343-7. doi: 10.1136/adc.2010.205898. Epub 2011 Jan 30. — View Citation

Gulczynska E, Szczapa T, Hozejowski R, Borszewska-Kornacka MK, Rutkowska M. Fraction of Inspired Oxygen as a Predictor of CPAP Failure in Preterm Infants with Respiratory Distress Syndrome: A Prospective Multicenter Study. Neonatology. 2019;116(2):171-178. doi: 10.1159/000499674. Epub 2019 May 21. — View Citation

Hedstrom AB, Gove NE, Mayock DE, Batra M. Performance of the Silverman Andersen Respiratory Severity Score in predicting PCO(2) and respiratory support in newborns: a prospective cohort study. J Perinatol. 2018 May;38(5):505-511. doi: 10.1038/s41372-018-0049-3. Epub 2018 Feb 9. — View Citation

Jobe AH. Pulmonary surfactant therapy. N Engl J Med. 1993 Mar 25;328(12):861-8. Review. — View Citation

Li L, Yang Q, Li L, Guan J, Liu Z, Han J, Chao Y, Wang Z, Yu X. [The value of lung ultrasound score on evaluating clinical severity and prognosis in patients with acute respiratory distress syndrome]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2015 Jul;27(7):579-84. doi: 10.3760/cma.j.issn.2095-4352.2015.07.008. Chinese. — View Citation

McCord FB, Curstedt T, Halliday HL, McClure G, Reid MM, Robertson B. Surfactant treatment and incidence of intraventricular haemorrhage in severe respiratory distress syndrome. Arch Dis Child. 1988 Jan;63(1):10-6. — View Citation

Narendran V, Donovan EF, Hoath SB, Akinbi HT, Steichen JJ, Jobe AH. Early bubble CPAP and outcomes in ELBW preterm infants. J Perinatol. 2003 Apr-May;23(3):195-9. — View Citation

Pang H, Zhang B, Shi J, Zang J, Qiu L. Diagnostic value of lung ultrasound in evaluating the severity of neonatal respiratory distress syndrome. Eur J Radiol. 2019 Jul;116:186-191. doi: 10.1016/j.ejrad.2019.05.004. Epub 2019 May 7. — View Citation

Pillai MS, Sankar MJ, Mani K, Agarwal R, Paul VK, Deorari AK. Clinical prediction score for nasal CPAP failure in pre-term VLBW neonates with early onset respiratory distress. J Trop Pediatr. 2011 Aug;57(4):274-9. doi: 10.1093/tropej/fmq047. Epub 2010 Jun 16. — View Citation

Rocha G, Flôr-de-Lima F, Proença E, Carvalho C, Quintas C, Martins T, Freitas A, Paz-Dias C, Silva A, Guimarães H. Failure of early nasal continuous positive airway pressure in preterm infants of 26 to 30 weeks gestation. J Perinatol. 2013 Apr;33(4):297-301. doi: 10.1038/jp.2012.110. Epub 2012 Aug 30. — View Citation

Sweet DG, Carnielli V, Greisen G, Hallman M, Ozek E, Plavka R, Saugstad OD, Simeoni U, Speer CP, Vento M, Visser GH, Halliday HL. European Consensus Guidelines on the Management of Respiratory Distress Syndrome - 2016 Update. Neonatology. 2017;111(2):107-125. doi: 10.1159/000448985. Epub 2016 Sep 21. — View Citation

Sweet DG, Carnielli V, Greisen G, Hallman M, Ozek E, Te Pas A, Plavka R, Roehr CC, Saugstad OD, Simeoni U, Speer CP, Vento M, Visser GHA, Halliday HL. European Consensus Guidelines on the Management of Respiratory Distress Syndrome - 2019 Update. Neonatology. 2019;115(4):432-450. doi: 10.1159/000499361. Epub 2019 Apr 11. — View Citation

Trachsel D, McCrindle BW, Nakagawa S, Bohn D. Oxygenation index predicts outcome in children with acute hypoxemic respiratory failure. Am J Respir Crit Care Med. 2005 Jul 15;172(2):206-11. Epub 2005 Apr 7. — View Citation

Walsh BK, Daigle B, DiBlasi RM, Restrepo RD; American Association for Respiratory Care. AARC Clinical Practice Guideline. Surfactant replacement therapy: 2013. Respir Care. 2013 Feb;58(2):367-75. doi: 10.4187/respcare.02189. — View Citation

* Note: There are 19 references in all — Click here to view all references

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Respiratory pulmonary function	The oxygen saturation (SpO2) to fraction of inspired oxygen (FiO2) ratio (SFR)	At day 3 of life
Secondary	Endotracheal intubation	The need of endotracheal intubation after surfactant administration	At day 3, 7 and 28 of life, and at 36 weeks of postmenstrual age or at the discharge if it occurs first
Secondary	Oxygen therapy	The need of oxygen therapy	At day 3, 7 and 28 of life, and at 36 weeks of postmenstrual age or at the discharge if it occurs first
Secondary	Respiratory Support-1	The need of respiratory support	At day 3, 7 and 28 of life, and at 36 weeks of postmenstrual age or at the discharge if it occurs first
Secondary	Respiratory Support-1	Oxygenation index as indicator of the intensity of ventilatory	At day 3, 7 and 28 of life, and at 36 weeks of postmenstrual age or at the discharge if it occurs first
Secondary	Respiratory severity-1	Silvermann score as secondary respiratory severity index	At day 3, 7 and 28 of life, and at 36 weeks of postmenstrual age or at the discharge if it occurs first
Secondary	Respiratory severity-2	Lung ultrasound score (LUS) score as secondary respiratory severity index	At day 3, 7 and 28 of life, and at 36 weeks of postmenstrual age or at the discharge if it occurs first
Secondary	Long-term respiratory pulmonary function	The oxygen saturation (SpO2) to fraction of inspired oxygen (FiO2) ratio (SFR)	At day 7 and 28 of life, and at 36 weeks of postmenstrual age or at the discharge if it occurs first, and 1 year of corrected age
Secondary	Complications of prematurity	The incidence of intraventricular hemorrhage of grade 3-4, periventricular leukomalacia, bronchopulmonary dysplasia, sepsis and retinopathy of prematurity	From birth to 36 weeks of postmenstrual age or discharge if it occurred first
Secondary	In-hospital death	death before 36 weeks of gestation	From birth to 36 week of gestation or discharge if it occurred first